ICU vs. ALUR, CLGN, NRXS, PSTV, NXL, IRIX, MHUA, XAIR, LYRA, and DHAI
Should you be buying SeaStar Medical stock or one of its competitors? The main competitors of SeaStar Medical include Allurion Technologies (ALUR), CollPlant Biotechnologies (CLGN), NeurAxis (NRXS), Plus Therapeutics (PSTV), Nexalin Technology (NXL), IRIDEX (IRIX), Meihua International Medical Technologies (MHUA), Beyond Air (XAIR), Lyra Therapeutics (LYRA), and DIH Holding US (DHAI). These companies are all part of the "medical equipment" industry.
SeaStar Medical vs. Its Competitors
SeaStar Medical (NASDAQ:ICU) and Allurion Technologies (NYSE:ALUR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.
1.7% of SeaStar Medical shares are owned by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are owned by institutional investors. 1.3% of SeaStar Medical shares are owned by insiders. Comparatively, 22.4% of Allurion Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
SeaStar Medical has a beta of -1.09, suggesting that its share price is 209% less volatile than the S&P 500. Comparatively, Allurion Technologies has a beta of -0.47, suggesting that its share price is 147% less volatile than the S&P 500.
SeaStar Medical has a net margin of 0.00% compared to Allurion Technologies' net margin of -86.05%.
In the previous week, SeaStar Medical had 1 more articles in the media than Allurion Technologies. MarketBeat recorded 5 mentions for SeaStar Medical and 4 mentions for Allurion Technologies. SeaStar Medical's average media sentiment score of 0.06 beat Allurion Technologies' score of 0.00 indicating that SeaStar Medical is being referred to more favorably in the media.
SeaStar Medical has higher earnings, but lower revenue than Allurion Technologies. Allurion Technologies is trading at a lower price-to-earnings ratio than SeaStar Medical, indicating that it is currently the more affordable of the two stocks.
Allurion Technologies has a consensus price target of $22.83, indicating a potential upside of 668.80%. Given Allurion Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Allurion Technologies is more favorable than SeaStar Medical.
Summary
Allurion Technologies beats SeaStar Medical on 9 of the 16 factors compared between the two stocks.
Get SeaStar Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for ICU and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ICU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SeaStar Medical Competitors List
Related Companies and Tools
This page (NASDAQ:ICU) was last updated on 7/10/2025 by MarketBeat.com Staff
Free ICU Stock Alerts